



2ND NCRI AML ACADEMY

Diagnosis and Management of Adult AML: Where are we in 2020?

Thursday 8th & Friday 9th October 2020

IET Austin Court, 80 Cambridge Street, Birmingham B1 2NP

Organisers: Professor Charles Craddock (*Birmingham*)
Dr Mike Dennis (*Manchester*) & Dr Steve Knapper (*Cardiff*)

VIRTUAL EVENT for delegates

Thursday 8th October - NCRI AML Academy

Chair: Professor Charles Craddock, *Birmingham*

16.00	25 years of UK AML Trials - what have we learned?	Professor Alan Burnett, <i>POG-LR University of Glasgow</i> (Link)
16.30	AML 18, AML 19 and LI1	Professor Nigel Russell, <i>London</i> and Dr Mike Dennis, <i>Manchester</i>
17.00	Transplant trials	Dr Victoria Potter, <i>London</i>
17.20	MRD - update and cases	Dr Richard Dillon, <i>London</i> and Professor Sylvie Freeman, <i>Birmingham</i>
17.55	<i>Coffee</i>	
18.15	AML 20 and supportive care	Professor Charles Craddock, <i>Birmingham</i> , Dr Steve Knapper, <i>Cardiff</i> and Dr Simon Stanworth, <i>Oxford</i>
18.55	EVOLVE	Professor Paresh Vyas, <i>Oxford</i> and Dr Mike Dennis, <i>Manchester</i>
19.25	<i>Close of Day One</i>	

Friday 9th October - NCRI AML Academy

Plenary Session

Chairs: Dr Steve Knapper, *Cardiff* and Professor Sylvie Freeman, *Birmingham*

09.30	Genomics in the diagnosis and management of AML in 2020	Professor Brian Huntly, <i>Cambridge</i>
09.55	Novel therapeutic strategies in relapsed AML	Professor Paresh Vyas, <i>Oxford</i> and Dr Victoria Potter, <i>London</i>

David Grimwade Memorial Lecture

Chair: Professor Charles Craddock, *Birmingham*

10.20	Advances in the management of APML	Professor Uwe Platzbecker, <i>Leipzig, Germany</i> (<i>Recorded</i>)
10.50	Discussion	<i>Live link for questions</i>
11.00	<i>Coffee</i>	

Friday 9th October - NCRI AML Academy (continued)

11.15	Transplant Roundtable Workshop Presented cases for panel discussion	Chair: Dr Victoria Potter , <i>London</i> Panel: Dr Erin Hurst, <i>Newcastle</i> Dr Rachel Protheroe, <i>Bristol</i> Dr Eleni Tholouli, <i>Manchester</i> Dr Wendy Ingram, <i>Cardiff</i> <i>Recorded case studies - live in Birmingham for interactive roundtable on stage</i>
12.15	<i>Lunch</i>	
13.00	Plenary Session Venetoclax as a potential game-changer in the management of older (and younger) adults with AML Discussion Emerging drug and antibody targeted therapies in AML Questions and discussion	Chair: Dr Mike Dennis , <i>Manchester</i> Professor Andrew Wei, <i>Melbourne, Australia</i> <i>(Recorded)</i> Professor Naval Daver, <i>MD Anderson, Texas</i> <i>(Recorded)</i> <i>Live link to speakers for Q & A</i>
14.25	<i>Coffee</i>	
14.45	Debate DA is still the standard induction therapy for all fit AML patients in the UK	Chair: Dr Steve Knapper , <i>Cardiff</i> For: Dr Priyanka Mehta, <i>Bristol</i> Dr Eleni Tholouli, <i>Manchester</i> Against: Professor Asim Khwaja, <i>London</i> Dr Paul Cahalin, <i>Blackpool</i>
15.45	Summary	Professor Charles Craddock, <i>Birmingham</i>
15.45	<i>Close of main session</i>	
15.55	Nurses session	Sarah Watmough and Kirsty Halliwell <i>AML Trials Unit</i>
16.45	<i>Close</i>	

REGISTRATION:

For further information about this meeting or to register, please visit www.hartleytaylor.co.uk/ncri-aml/

ENQUIRIES:

Please contact anne@hartleytaylor.co.uk

abbvie

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

astellas

Celgene | Bristol Myers Squibb
Company

NOVARTIS

Daiichi-Sankyo

astex
A member of the Otsuka group

Jazz Pharmaceuticals

medac
PHARMA

AMGEN
Oncology

eurocept
international

Incyte

The sponsors have had no input into the programme or choice of speakers